Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Celularity announces $30M private placement » 08:36
05/18/22
05/18
08:36
05/18/22
08:36
CELU

Celularity

$7.60 /

+1.14 (+17.65%)

Celularity announced that…

Celularity announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 per share and warrants to purchase 4,054,055 shares of its Class A common stock at an exercise price of $8.25 per share in a private placement priced at-the-market under Nasdaq rules, resulting in total gross proceeds of approximately $30.0 million before deducting placement agent commissions and other estimated offering expenses. The warrants will be exercisable immediately after the date of issuance and will expire five years following the initial issuance date. The closing of the offering and sale of the Securities is expected to occur on or about May 20, 2022, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

ShowHide Related Items >><<
CELU Celularity
$7.60 /

+1.14 (+17.65%)

CELU Celularity
$7.60 /

+1.14 (+17.65%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
CELU Celularity
$7.60 /

+1.14 (+17.65%)

CELU Celularity
$7.60 /

+1.14 (+17.65%)

Monday
Options
Celularity options imply 28.6% move in share price post-earnings » 15:19
05/16/22
05/16
15:19
05/16/22
15:19
CELU

Celularity

$6.66 /

-0.7 (-9.51%)

Pre-earnings options…

Pre-earnings options volume in Celularity is normal with calls leading puts 7:4. Implied volatility suggests the market is anticipating a move near 28.6%, or 0c, after results are released. Median move over the past eight quarters is 1.3%.

ShowHide Related Items >><<
CELU Celularity
$6.66 /

-0.7 (-9.51%)

CELU Celularity
$6.66 /

-0.7 (-9.51%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
CELU Celularity
$6.66 /

-0.7 (-9.51%)

CELU Celularity
$6.66 /

-0.7 (-9.51%)

Options
Largest borrow rate increases among liquid names » 08:45
05/16/22
05/16
08:45
05/16/22
08:45
MDVL

Medavail

$2.09 /

-0.215 (-9.35%)

, EMBK

Embark Technology

$2.38 /

+0.45 (+23.32%)

, FSR

Fisker

$9.87 /

+0.545 (+5.84%)

, HUT

Hut 8 Mining

$2.74 /

+0.305 (+12.55%)

, EQNR

Equinor

$33.89 /

+0.14 (+0.41%)

, BNGO

Bionano Genomics

$1.62 /

+0.22 (+15.71%)

, ANY

Sphere 3D

$1.05 /

+0.1133 (+12.16%)

, NU

Nu Holdings

$4.80 /

+0.81 (+20.30%)

, NKLA

Nikola

$6.41 /

+0.87 (+15.70%)

, CELU

Celularity

$7.35 /

+1.575 (+27.27%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: MedAvail Holdings (MDVL) 100.70% +7.01, Embark Technology (EMBK) 18.16% +4.48, Fisker (FSR) 31.01% +3.34, Hut 8 Mining (HUT) 5.52% +0.97, Equinor (EQNR) 10.59% +0.88, Bionano Genomics (BNGO) 3.02% +0.87, Sphere 3D (ANY) 14.68% +0.66, Nu Holdings (NU) 64.06% +0.55, Nikola (NKLA) 18.13% +0.50, and Celularity (CELU) 80.33% +0.47.

ShowHide Related Items >><<
NU Nu Holdings
$4.80 /

+0.81 (+20.30%)

NKLA Nikola
$6.41 /

+0.87 (+15.70%)

MDVL Medavail
$2.09 /

-0.215 (-9.35%)

HUT Hut 8 Mining
$2.74 /

+0.305 (+12.55%)

FSR Fisker
$9.87 /

+0.545 (+5.84%)

EQNR Equinor
$33.89 /

+0.14 (+0.41%)

EMBK Embark Technology
$2.38 /

+0.45 (+23.32%)

CELU Celularity
$7.35 /

+1.575 (+27.27%)

BNGO Bionano Genomics
$1.62 /

+0.22 (+15.71%)

ANY Sphere 3D
$1.05 /

+0.1133 (+12.16%)

MDVL Medavail
$2.09 /

-0.215 (-9.35%)

08/30/21 Cowen
Medavail price target lowered to $9.50 from $20 at Cowen
08/12/21 Lake Street
Medavail price target lowered to $8 from $18 at Lake Street
EMBK Embark Technology
$2.38 /

+0.45 (+23.32%)

05/11/22 Citi
Embark Technology price target lowered to $6 from $11 at Citi
04/26/22 Vertical Research
Embark Technology initiated with a Buy at Vertical Research
03/18/22 Baird
Embark Technology price target lowered to $9 from $12 at Baird
01/11/22 KeyBanc
KeyBanc initiates Embark Technology with a Sector Weight
FSR Fisker
$9.87 /

+0.545 (+5.84%)

05/05/22 Cowen
Fisker price target lowered to $19 from $28 at Cowen
05/05/22 Barclays
Fisker price target lowered to $14 from $16 at Barclays
05/05/22 Citi
Fisker price target lowered to $27 from $29 at Citi
04/11/22 Exane BNP Paribas
Fisker initiated with an Outperform at Exane BNP Paribas
HUT Hut 8 Mining
$2.74 /

+0.305 (+12.55%)

05/13/22 Canaccord
Hut 8 Mining price target lowered to $6 from $12 at Canaccord
03/24/22 Stifel
Hut 8 Mining resumed with a Speculative Buy at Stifel
03/22/22 Canaccord
Hut 8 Mining price target lowered to $12 from $20 at Canaccord
11/12/21 Canaccord
Hut 8 Mining price target raised to $20 from $12 at Canaccord
EQNR Equinor
$33.89 /

+0.14 (+0.41%)

05/13/22 Jefferies
Equinor downgraded to Hold on valuation at Jefferies
05/13/22 Jefferies
Equinor downgraded to Hold from Buy at Jefferies
05/11/22 Morgan Stanley
Equinor price target raised to NOK 287 from NOK 280 at Morgan Stanley
05/09/22 RBC Capital
Equinor downgraded to Sector Perform from Outperform at RBC Capital
BNGO Bionano Genomics
$1.62 /

+0.22 (+15.71%)

04/07/22 BTIG
Bionano Genomics price target lowered to $7 from $10 at BTIG
12/27/21 Oppenheimer
Oppenheimer bullish on Bionano Genomics, sees potential Q4 upside
06/16/21 BTIG
Bionano Genomics initiated with a Buy at BTIG
ANY Sphere 3D
$1.05 /

+0.1133 (+12.16%)

10/28/21 PI Financial
Sphere 3D initiated with a Buy at PI Financial
NU Nu Holdings
$4.80 /

+0.81 (+20.30%)

05/13/22 Susquehanna
Nu Holdings price target lowered to $10 from $14 at Susquehanna
04/05/22 MoffettNathanson
Nu Holdings initiated with a Buy at MoffettNathanson
02/16/22 Bradesco BBI
Nu Holdings initiated with an Underperform at Bradesco BBI
01/28/22 BofA
BofA starts Nu Holdings at Neutral, sees balanced risk-reward
NKLA Nikola
$6.41 /

+0.87 (+15.70%)

05/10/22 Wedbush
Nikola price target lowered to $10 from $15 at Wedbush
03/25/22 Wedbush
Nikola's analyst day sets bullish tone for 2022, beyond, says Wedbush
03/24/22 Deutsche Bank
Deutsche Bank left Nikola analyst day 'highly encouraged'
03/10/22 JPMorgan
Nikola is tracking to 2022 goals, says JPMorgan
CELU Celularity
$7.35 /

+1.575 (+27.27%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
NU Nu Holdings
$4.80 /

+0.81 (+20.30%)

NKLA Nikola
$6.41 /

+0.87 (+15.70%)

MDVL Medavail
$2.09 /

-0.215 (-9.35%)

HUT Hut 8 Mining
$2.74 /

+0.305 (+12.55%)

FSR Fisker
$9.87 /

+0.545 (+5.84%)

BNGO Bionano Genomics
$1.62 /

+0.22 (+15.71%)

  • 09
    Dec
  • 15
    Sep
  • 25
    May
NKLA Nikola
$6.41 /

+0.87 (+15.70%)

FSR Fisker
$9.87 /

+0.545 (+5.84%)

EQNR Equinor
$33.89 /

+0.14 (+0.41%)

NU Nu Holdings
$4.80 /

+0.81 (+20.30%)

NKLA Nikola
$6.41 /

+0.87 (+15.70%)

MDVL Medavail
$2.09 /

-0.215 (-9.35%)

HUT Hut 8 Mining
$2.74 /

+0.305 (+12.55%)

FSR Fisker
$9.87 /

+0.545 (+5.84%)

EMBK Embark Technology
$2.38 /

+0.45 (+23.32%)

CELU Celularity
$7.35 /

+1.575 (+27.27%)

BNGO Bionano Genomics
$1.62 /

+0.22 (+15.71%)

ANY Sphere 3D
$1.05 /

+0.1133 (+12.16%)

NU Nu Holdings
$4.80 /

+0.81 (+20.30%)

NKLA Nikola
$6.41 /

+0.87 (+15.70%)

MDVL Medavail
$2.09 /

-0.215 (-9.35%)

HUT Hut 8 Mining
$2.74 /

+0.305 (+12.55%)

FSR Fisker
$9.87 /

+0.545 (+5.84%)

EMBK Embark Technology
$2.38 /

+0.45 (+23.32%)

CELU Celularity
$7.35 /

+1.575 (+27.27%)

ANY Sphere 3D
$1.05 /

+0.1133 (+12.16%)

Over a week ago
Options
Celularity options imply 18.1% move in share price post-earnings » 13:04
05/13/22
05/13
13:04
05/13/22
13:04
CELU

Celularity

$7.93 /

+2.155 (+37.32%)

Pre-earnings options…

Pre-earnings options volume in Celularity is normal with puts leading calls 2:1. Implied volatility suggests the market is anticipating a move near 18.1%, or 0c, after results are released. Median move over the past eight quarters is 1.3%.

ShowHide Related Items >><<
CELU Celularity
$7.93 /

+2.155 (+37.32%)

CELU Celularity
$7.93 /

+2.155 (+37.32%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
CELU Celularity
$7.93 /

+2.155 (+37.32%)

CELU Celularity
$7.93 /

+2.155 (+37.32%)

Options
Largest borrow rate increases among liquid names » 08:45
05/10/22
05/10
08:45
05/10/22
08:45
EVTL

Vertical Aerospace

$6.74 /

-0.52 (-7.16%)

, ARCH

Arch Resources

$159.66 /

-14.7 (-8.43%)

, SG

Sweetgreen

$20.42 /

-3.365 (-14.15%)

, TKAT

Takung Art

$1.91 /

-0.05 (-2.55%)

, ATOM

Atomera

$11.43 /

-0.57 (-4.75%)

, CS

Credit Suisse

$6.27 /

-0.299366 (-4.56%)

, LCID

Lucid Group

$16.37 /

-1.78 (-9.81%)

, IMPP

Imperial Petroleum

/

+

, NU

Nu Holdings

$4.38 /

-0.84 (-16.09%)

, CELU

Celularity

$9.08 /

-3.135 (-25.68%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Vertical Aerospace (EVTL) 500.04% +13.92, Arch Coal (ARCH) 10.68% +4.15, Sweetgreen (SG) 69.90% +3.47, Takung Art (TKAT) 66.30% +2.68, Atomera (ATOM) 5.76% +1.14, Credit Suisse (CS) 3.06% +0.76, Lucid Group (LCID) 10.12% +0.73, Imperial Petroleum (IMPP) 39.39% +0.48, Nu Holdings (NU) 29.50% +0.45, and Celularity (CELU) 84.04% +0.39.

ShowHide Related Items >><<
TKAT Takung Art
$1.91 /

-0.05 (-2.55%)

SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

NU Nu Holdings
$4.38 /

-0.84 (-16.09%)

LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

IMPP Imperial Petroleum
/

+

EVTL Vertical Aerospace
$6.74 /

-0.52 (-7.16%)

CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

CELU Celularity
$9.08 /

-3.135 (-25.68%)

ATOM Atomera
$11.43 /

-0.57 (-4.75%)

ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

EVTL Vertical Aerospace
$6.74 /

-0.52 (-7.16%)

04/11/22 Deutsche Bank
Vertical Aerospace initiated with a Hold at Deutsche Bank
01/18/22 Barclays
Vertical Aerospace initiated with an Underweight at Barclays
ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

04/27/22 B. Riley
Arch Resources price target raised to $234 from $231 at B. Riley
03/09/22 Jefferies
Arch Resources price target raised to $150 from $130 at Jefferies
03/08/22 B. Riley
Arch Resources price target raised to $231 from $174 at B. Riley
02/16/22 BMO Capital
Arch Resources price target raised to $140 from $115 at BMO Capital
SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

04/12/22 Citi
Sweetgreen initiated with a Neutral at Citi
03/17/22 Cowen
Cowen favors domestic restaurant chains as inflation hurts sector
03/04/22 Morgan Stanley
Morgan Stanley says first post-IPO report a positive for Sweetgreen shares
03/04/22 Oppenheimer
Sweetgreen price target lowered to $37 from $41 at Oppenheimer
TKAT Takung Art
$1.91 /

-0.05 (-2.55%)

ATOM Atomera
$11.43 /

-0.57 (-4.75%)

02/16/22 Craig-Hallum
Atomera price target lowered to $22 from $28 at Craig-Hallum
06/09/21 Craig-Hallum
Atomera initiated with a Buy at Craig-Hallum
CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

04/29/22 JPMorgan
Credit Suisse price target lowered to CHF 6.60 from CHF 7.90 at JPMorgan
04/21/22 Morgan Stanley
Credit Suisse price target lowered to CHF 9.50 from CHF 10.50 at Morgan Stanley
04/14/22 Deutsche Bank
Credit Suisse price target lowered to CHF 8 from CHF 11 at Deutsche Bank
03/30/22 Goldman Sachs
Credit Suisse initiated with a Neutral at Goldman Sachs
LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

05/09/22 Citi
Lucid Group price target lowered to $36 from $45 at Citi
05/06/22 Morgan Stanley
Lucid production view looks more bull case than base case, says Morgan Stanley
04/25/22 Wells Fargo
Wells says Wolfspeed design win with Lucid further validation of SiC portfolio
04/11/22 Exane BNP Paribas
Lucid Group initiated with an Outperform at Exane BNP Paribas
IMPP Imperial Petroleum
/

+

NU Nu Holdings
$4.38 /

-0.84 (-16.09%)

04/05/22 MoffettNathanson
Nu Holdings initiated with a Buy at MoffettNathanson
02/16/22 Bradesco BBI
Nu Holdings initiated with an Underperform at Bradesco BBI
01/28/22 BofA
BofA starts Nu Holdings at Neutral, sees balanced risk-reward
01/28/22 BofA
Nu Holdings initiated with a Neutral at BofA
CELU Celularity
$9.08 /

-3.135 (-25.68%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

NU Nu Holdings
$4.38 /

-0.84 (-16.09%)

LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

IMPP Imperial Petroleum
/

+

CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

CELU Celularity
$9.08 /

-3.135 (-25.68%)

ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

  • 21
    Mar
  • 09
    Dec
  • 18
    Nov
SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

NU Nu Holdings
$4.38 /

-0.84 (-16.09%)

LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

IMPP Imperial Petroleum
/

+

EVTL Vertical Aerospace
$6.74 /

-0.52 (-7.16%)

CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

CELU Celularity
$9.08 /

-3.135 (-25.68%)

ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

TKAT Takung Art
$1.91 /

-0.05 (-2.55%)

SG Sweetgreen
$20.42 /

-3.365 (-14.15%)

NU Nu Holdings
$4.38 /

-0.84 (-16.09%)

LCID Lucid Group
$16.37 /

-1.78 (-9.81%)

IMPP Imperial Petroleum
/

+

EVTL Vertical Aerospace
$6.74 /

-0.52 (-7.16%)

CS Credit Suisse
$6.27 /

-0.299366 (-4.56%)

CELU Celularity
$9.08 /

-3.135 (-25.68%)

ATOM Atomera
$11.43 /

-0.57 (-4.75%)

ARCH Arch Resources
$159.66 /

-14.7 (-8.43%)

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 04:55
05/04/22
05/04
04:55
05/04/22
04:55
ABBV

AbbVie

$149.61 /

+1.74 (+1.18%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.15 /

+0.03 (+2.69%)

, AERI

Aerie Pharmaceuticals

$7.96 /

+0.47 (+6.28%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$16.04 /

+0.23 (+1.45%)

, BMRN

BioMarin

$83.49 /

+0.18 (+0.22%)

, CE

Celanese

$150.37 /

+4.53 (+3.11%)

, CELU

Celularity

$11.38 /

-0.28 (-2.40%)

, DNA

Ginkgo Bioworks

$3.23 /

+0.105 (+3.36%)

, EDIT

Editas Medicine

$14.18 /

-0.1 (-0.70%)

, HZNP

Horizon Therapeutics

$94.70 /

-3.375 (-3.44%)

, JNJ

Johnson & Johnson

$178.28 /

-0.37 (-0.21%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.39 /

-0.065 (-1.01%)

, LCTX

Lineage Cell Therapeutics

$1.27 /

+0.065 (+5.39%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$660.09 /

+7.73 (+1.18%)

, RGNX

Regenxbio

$28.25 /

-0.15 (-0.53%)

, RHHBY

Roche

$45.13 /

-0.37 (-0.81%)

, STOK

Stoke Therapeutics

$14.77 /

-0.21 (-1.40%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

05/03/22 Morgan Stanley
Vertex upgraded to Equal Weight at Morgan Stanley following AbbVie failure
05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$150.37 /

+4.53 (+3.11%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.38 /

-0.28 (-2.40%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$660.09 /

+7.73 (+1.18%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$45.13 /

-0.37 (-0.81%)

05/03/22 Piper Sandler
Piper keeps Overweight rating on Ionis after Biogen's Spinraza beat
04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ADVM Adverum Biotechnologies
$1.15 /

+0.03 (+2.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$45.13 /

-0.37 (-0.81%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

LCTX Lineage Cell Therapeutics
$1.27 /

+0.065 (+5.39%)

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BAYRY Bayer
$16.04 /

+0.23 (+1.45%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

STOK Stoke Therapeutics
$14.77 /

-0.21 (-1.40%)

RHHBY Roche
$45.13 /

-0.37 (-0.81%)

RGNX Regenxbio
$28.25 /

-0.15 (-0.53%)

REGN Regeneron
$660.09 /

+7.73 (+1.18%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.39 /

-0.065 (-1.01%)

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

HZNP Horizon Therapeutics
$94.70 /

-3.375 (-3.44%)

EDIT Editas Medicine
$14.18 /

-0.1 (-0.70%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

BMRN BioMarin
$83.49 /

+0.18 (+0.22%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.96 /

+0.47 (+6.28%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.28 /

-0.37 (-0.21%)

DNA Ginkgo Bioworks
$3.23 /

+0.105 (+3.36%)

CELU Celularity
$11.38 /

-0.28 (-2.40%)

CE Celanese
$150.37 /

+4.53 (+3.11%)

ABBV AbbVie
$149.61 /

+1.74 (+1.18%)

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 04:55
05/03/22
05/03
04:55
05/03/22
04:55
ABBV

AbbVie

$147.87 /

+1.03 (+0.70%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.11 /

+0.045 (+4.23%)

, AERI

Aerie Pharmaceuticals

$7.50 /

+0.385 (+5.41%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$15.81 /

-0.575 (-3.51%)

, BMRN

BioMarin

$83.30 /

+1.935 (+2.38%)

, CE

Celanese

$145.86 /

-1.025 (-0.70%)

, CELU

Celularity

$11.65 /

-0.055 (-0.47%)

, DNA

Ginkgo Bioworks

$3.13 /

+0.23 (+7.94%)

, EDIT

Editas Medicine

$14.28 /

+1.03 (+7.77%)

, HZNP

Horizon Therapeutics

$98.08 /

-0.445 (-0.45%)

, JNJ

Johnson & Johnson

$178.65 /

-1.98 (-1.10%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.45 /

+0.425 (+7.06%)

, LCTX

Lineage Cell Therapeutics

$1.21 /

-0.01 (-0.82%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$652.21 /

-6.68 (-1.01%)

, RGNX

Regenxbio

$28.42 /

+0.67 (+2.41%)

, RHHBY

Roche

$45.50 /

-0.68 (-1.47%)

, STOK

Stoke Therapeutics

$14.98 /

+0.58 (+4.03%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
05/02/22 JPMorgan
AbbVie selloff Friday 'very much overdone,' says JPMorgan
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$145.86 /

-1.025 (-0.70%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.65 /

-0.055 (-0.47%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$652.21 /

-6.68 (-1.01%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$45.50 /

-0.68 (-1.47%)

04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
04/14/22 Barclays
Roche price target raised to CHF 450 from CHF 415 at Barclays
STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ADVM Adverum Biotechnologies
$1.11 /

+0.045 (+4.23%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$45.50 /

-0.68 (-1.47%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

LCTX Lineage Cell Therapeutics
$1.21 /

-0.01 (-0.82%)

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BAYRY Bayer
$15.81 /

-0.575 (-3.51%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

STOK Stoke Therapeutics
$14.98 /

+0.58 (+4.03%)

RHHBY Roche
$45.50 /

-0.68 (-1.47%)

RGNX Regenxbio
$28.42 /

+0.67 (+2.41%)

REGN Regeneron
$652.21 /

-6.68 (-1.01%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.45 /

+0.425 (+7.06%)

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

HZNP Horizon Therapeutics
$98.08 /

-0.445 (-0.45%)

EDIT Editas Medicine
$14.28 /

+1.03 (+7.77%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

BMRN BioMarin
$83.30 /

+1.935 (+2.38%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.50 /

+0.385 (+5.41%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$178.65 /

-1.98 (-1.10%)

DNA Ginkgo Bioworks
$3.13 /

+0.23 (+7.94%)

CELU Celularity
$11.65 /

-0.055 (-0.47%)

CE Celanese
$145.86 /

-1.025 (-0.70%)

ABBV AbbVie
$147.87 /

+1.03 (+0.70%)

Conference/Events
Association for Research in Vision & Ophthalmology to hold annual meeting » 09:48
05/02/22
05/02
09:48
05/02/22
09:48
ABBV

AbbVie

$146.26 /

-0.58 (-0.39%)

, ABEO

Abeona Therapeutics

/

+

, ADVM

Adverum Biotechnologies

$1.12 /

+0.05 (+4.69%)

, AERI

Aerie Pharmaceuticals

$7.08 /

-0.03 (-0.42%)

, AGN

Bought by ABBV

$193.08 /

+ (+0.00%)

, AGTC

Applied Genetic

/

+

, BAYRY

Bayer

$16.39 /

+0.015 (+0.09%)

, BMRN

BioMarin

$81.76 /

+0.4 (+0.49%)

, CE

Celanese

$148.01 /

+1.13 (+0.77%)

, CELU

Celularity

$11.59 /

-0.115 (-0.98%)

, DNA

Ginkgo Bioworks

$2.81 /

-0.085 (-2.94%)

, EDIT

Editas Medicine

$13.28 /

+0.03 (+0.23%)

, HZNP

Horizon Therapeutics

$97.60 /

-0.92 (-0.93%)

, JNJ

Johnson & Johnson

$180.45 /

-0.185 (-0.10%)

, KALA

Kala Pharmaceuticals

/

+

, KOD

Kodiak Sciences

$6.03 /

+0.01 (+0.17%)

, LCTX

Lineage Cell Therapeutics

$1.18 /

-0.035 (-2.88%)

, PRQR

ProQR Therapeutics

/

+

, REGN

Regeneron

$658.67 /

-0.225 (-0.03%)

, RGNX

Regenxbio

$27.61 /

-0.14 (-0.50%)

, RHHBY

Roche

$46.18 /

-0.4 (-0.86%)

, STOK

Stoke Therapeutics

$14.40 /

+ (+0.00%)

, UBX

Unity Biotechnology

/

+

ARVO 2022 to be held in…

ARVO 2022 to be held in Denver, CO on May 1-4.

ShowHide Related Items >><<
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

05/02/22 Morgan Stanley
AbbVie's recent weakness a buying opportunity, says Morgan Stanley
05/02/22 Wells Fargo
AbbVie price target raised to $200 from $165 at Wells Fargo
05/02/22 Cowen
Genmab initiated with a Market Perform at Cowen
05/02/22 JPMorgan
AbbVie selloff Friday 'very much overdone,' says JPMorgan
ABEO Abeona Therapeutics
/

+

11/30/21 SVB Leerink
Abeona Therapeutics downgraded to Market Perform from Outperform at SVB Leerink
11/29/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
07/19/21 H.C. Wainwright
Abeona Therapeutics price target lowered to $5 from $8 at H.C. Wainwright
ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

03/29/22 Chardan
Adverum Biotechnologies transferred with Neutral at Chardan
07/23/21
Fly Intel: Top five analyst downgrades
07/23/21 Goldman Sachs
Adverum Biotechnologies downgraded to Neutral from Buy at Goldman Sachs
07/23/21 SVB Leerink
Adverum Biotechnologies price target lowered to $2 from $5
AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

02/28/22 Citi
Aerie Pharmaceuticals price target lowered to $13 from $23 at Citi
02/25/22 Cowen
Aerie Pharmaceuticals price target lowered to $25 from $30 at Cowen
AGN Bought by ABBV
$193.08 /

+ (+0.00%)

AGTC Applied Genetic
/

+

03/29/22 Chardan
Applied Genetic transferred with Buy rating at Chardan
02/14/22 Stifel
Stifel keeps Buy rating on Applied Genetic, lowers price target to $10
09/24/21 Roth Capital
Applied Genetic near-term readouts 'major catalysts,' says Roth Capital
07/09/21 Chardan
Applied Genetic coverage transferred at Chardan
BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

04/25/22 Morgan Stanley
Bayer price target raised to EUR 83 from EUR 77 at Morgan Stanley
04/05/22 Barclays
Bayer upgraded to Overweight from Equal Weight at Barclays
03/15/22 Barclays
Bayer price target raised to EUR 60 from EUR 55 at Barclays
03/14/22 Jefferies
Bayer initiated with a Buy at Jefferies
BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

04/28/22 Wedbush
BioMarin price target lowered to $147 from $155 at Wedbush
04/25/22 Morgan Stanley
BioMarin upgraded to Overweight from Equal Weight at Morgan Stanley
02/24/22 Piper Sandler
BioMarin price target raised to $125 from $121 at Piper Sandler
01/10/22 JPMorgan
JPMorgan bullish on BioMarin following CEO 'encouraging' presentation
CE Celanese
$148.01 /

+1.13 (+0.77%)

04/13/22 Fermium Research
DuPont price target lowered to $78 from $87 at Fermium Research
04/08/22 JPMorgan
Celanese added to Analyst Focus List at JPMorgan
02/22/22 Deutsche Bank
Celanese likely to split-up in 2024 or 2025, says Deutsche Bank
02/22/22 Piper Sandler
Celanese downgraded to Underweight from Neutral at Piper Sandler
CELU Celularity
$11.59 /

-0.115 (-0.98%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

03/31/22 BTIG
Ginkgo Bioworks price target lowered to $6 from $12 at BTIG
03/29/22 Cowen
Ginkgo Bioworks weakness a buying opportunity, says Cowen
03/02/22 Cowen
Ginkgo Bioworks initiated with an Outperform at Cowen
02/23/22 Goldman Sachs
Ginkgo Bioworks initiated with a Neutral at Goldman Sachs
EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

04/18/22 Baird
Editas Medicine price target lowered to $33 from $44 at Baird
02/25/22 SVB Leerink
Editas Medicine price target lowered to $27 from $41 at SVB Leerink
02/25/22 Barclays
Editas Medicine price target lowered to $18 from $39 at Barclays
02/25/22 Chardan
Editas Medicine price target lowered to $60 from $75 at Chardan
HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

03/14/22 Oppenheimer
Horizon Therapeutics initiated with an Outperform at Oppenheimer
01/26/22 Piper Sandler
Horizon Therapeutics price target lowered to $133 from $143 at Piper Sandler
01/18/22 JPMorgan
Horizon Therapeutics valuation 'compelling' after selloff, says JPMorgan
12/08/21
Fly Intel: Top five analyst initiations
JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

04/29/22 Chardan
Emergent BioSolutions price target lowered to $65 from $75 at Chardan
04/20/22 Credit Suisse
Johnson & Johnson price target raised to $205 from $200 at Credit Suisse
04/20/22 Citi
Johnson & Johnson price target raised to $210 from $203 at Citi
04/19/22 Stifel
J&J notes more-positive Q1 trends, U.S. Spine 'a relative outlier,' says Stifel
KALA Kala Pharmaceuticals
/

+

03/30/22 Northland
Kala Pharmaceuticals price target lowered to $4 from $6 at Northland
03/30/22 H.C. Wainwright
Kala Pharmaceuticals price target lowered to $6 from $9 at H.C. Wainwright
03/30/22 JPMorgan
Kala Pharmaceuticals downgraded to Underweight from Neutral at JPMorgan
12/15/21 Wedbush
Kala Pharmaceuticals assumed with an Outperform, $6 target at Wedbush
KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

04/13/22 Truist
Kodiak Sciences price target lowered to $10 from $35 at Truist
03/29/22 Chardan
Kodiak Sciences price target lowered to $19 from $82.50 at Chardan
02/28/22 Roth Capital
Kodiak Sciences price target lowered to $75 from $149 at Roth Capital
02/24/22 Truist
Kodiak Sciences price target lowered to $35 from $147 at Truist
LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

04/25/22 H.C. Wainwright
Lineage Cell's PNC program 'an expected and logical move,' says H.C. Wainwright
08/19/21 Noble Capital
Lineage Cell Therapeutics initiated with an Outperform at Noble Capital
PRQR ProQR Therapeutics
/

+

04/19/22 Cantor Fitzgerald
ProQR Therapeutics price target lowered to $3.50 from $6.00 at Cantor Fitzgerald
04/14/22 Chardan
ProQR Therapeutics price target lowered to $2.50 from $8 at Chardan
03/15/22 Citi
ProQR Therapeutics price target lowered to $1 from $1.70 at Citi
02/14/22 Citi
ProQR Therapeutics downgraded to Neutral from Buy at Citi
REGN Regeneron
$658.67 /

-0.225 (-0.03%)

04/20/22 Cowen
Regeneron price target raised to $645 from $640 at Cowen
04/20/22 BTIG
Checkmate Pharmaceuticals downgraded to Neutral from Buy at BTIG
04/19/22 Baird
Decibel could be next target for Regeneron, says Baird
04/12/22 Barclays
Regeneron price target raised to $745 from $700 at Barclays
RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

03/29/22 Chardan
Regenxbio price target lowered to $76 from $90 at Chardan
02/10/22 SVB Leerink
Regenxbio price target lowered to $29 from $35 at SVB Leerink
12/15/21
Fly Intel: Top five analyst initiations
12/15/21 Wedbush
Wedbush initiates Regenxbio with a Neutral rating, price target of $29
RHHBY Roche
$46.18 /

-0.4 (-0.86%)

04/26/22 Stifel
Arvinas price target lowered to $85 from $93 at Stifel
04/19/22 UBS
Roche downgraded to Sell from Neutral at UBS
04/14/22 Barclays
Roche price target raised to CHF 450 from CHF 415 at Barclays
STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

01/31/22 Jefferies
Stoke Therapeutics initiated with a Buy at Jefferies
12/03/21
Fly Intel: Top five analyst initiations
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
12/03/21 BofA
Stoke Therapeutics initiated with a Buy at BofA
UBX Unity Biotechnology
/

+

01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy at Roth Capital on 2022 clinical plans
01/04/22 Roth Capital
Unity Biotechnology upgraded to Buy from Neutral at Roth Capital
12/15/21 Wedbush
Wedbush bullish on Unity Biotechnology, initiates with an Outperform
12/15/21 Wedbush
Unity Biotechnology assumed with an Outperform at Wedbush
UBX Unity Biotechnology
/

+

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ADVM Adverum Biotechnologies
$1.12 /

+0.05 (+4.69%)

ABEO Abeona Therapeutics
/

+

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

  • 22
    Mar
  • 17
    Dec
RHHBY Roche
$46.18 /

-0.4 (-0.86%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

LCTX Lineage Cell Therapeutics
$1.18 /

-0.035 (-2.88%)

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BAYRY Bayer
$16.39 /

+0.015 (+0.09%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

STOK Stoke Therapeutics
$14.40 /

+ (+0.00%)

RHHBY Roche
$46.18 /

-0.4 (-0.86%)

RGNX Regenxbio
$27.61 /

-0.14 (-0.50%)

REGN Regeneron
$658.67 /

-0.225 (-0.03%)

PRQR ProQR Therapeutics
/

+

KOD Kodiak Sciences
$6.03 /

+0.01 (+0.17%)

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

HZNP Horizon Therapeutics
$97.60 /

-0.92 (-0.93%)

EDIT Editas Medicine
$13.28 /

+0.03 (+0.23%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

BMRN BioMarin
$81.76 /

+0.4 (+0.49%)

AGTC Applied Genetic
/

+

AERI Aerie Pharmaceuticals
$7.08 /

-0.03 (-0.42%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

KALA Kala Pharmaceuticals
/

+

JNJ Johnson & Johnson
$180.45 /

-0.185 (-0.10%)

DNA Ginkgo Bioworks
$2.81 /

-0.085 (-2.94%)

CELU Celularity
$11.59 /

-0.115 (-0.98%)

CE Celanese
$148.01 /

+1.13 (+0.77%)

ABBV AbbVie
$146.26 /

-0.58 (-0.39%)

Syndicate
Celularity files to sell 6.28M shares of common stock for holders  08:04
04/29/22
04/29
08:04
04/29/22
08:04
CELU

Celularity

$12.88 /

+0.77 (+6.36%)

 
ShowHide Related Items >><<
CELU Celularity
$12.88 /

+0.77 (+6.36%)

CELU Celularity
$12.88 /

+0.77 (+6.36%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
CELU Celularity
$12.88 /

+0.77 (+6.36%)

CELU Celularity
$12.88 /

+0.77 (+6.36%)

CELU Celularity
$12.88 /

+0.77 (+6.36%)

Options
Largest borrow rate increases among liquid names » 08:45
04/28/22
04/28
08:45
04/28/22
08:45
SFT

Shift Technologies

$1.41 /

-0.025 (-1.75%)

, SV

Spring Valley Acquisition Corp.

$10.10 /

+0.2 (+2.02%)

, NFE

New Fortress Energy

$39.98 /

-0.06 (-0.15%)

, MMAT

Meta Materials

$1.19 /

-0.045 (-3.64%)

, STRY

Starry

$8.29 /

+0.85 (+11.42%)

, FRO

Frontline

$8.50 /

+0.205 (+2.47%)

, CELU

Celularity

$12.11 /

+0.15 (+1.25%)

, CLVR

Clever Leaves

$1.47 /

+0.03 (+2.09%)

, ESSC

East Stone Acquisition

$10.56 /

-0.09 (-0.85%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Shift Technologies (SFT) 6.98% +2.64, Spring Valley Acquisition Corp (SV) 8.02% +1.42, New Fortress Energy (NFE) 1.03% +0.78, Meta Materials (MMAT) 10.73% +0.57, (STRY) 18.89% +0.50, Frontline (FRO) 7.63% +0.46, Celularity (CELU) 82.74% +0.36, ProShares Ultra (BOIL) 6.38% +0.25, Clever Leaves (CLVR) 35.94% +0.20, and East Stone Acquisition Corp (ESSC) 6.11% +0.19.

ShowHide Related Items >><<
SV Spring Valley Acquisition Corp.
$10.10 /

+0.2 (+2.02%)

STRY Starry
$8.29 /

+0.85 (+11.42%)

SFT Shift Technologies
$1.41 /

-0.025 (-1.75%)

NFE New Fortress Energy
$39.98 /

-0.06 (-0.15%)

MMAT Meta Materials
$1.19 /

-0.045 (-3.64%)

ESSC East Stone Acquisition
$10.56 /

-0.09 (-0.85%)

CLVR Clever Leaves
$1.47 /

+0.03 (+2.09%)

CELU Celularity
$12.11 /

+0.15 (+1.25%)

SFT Shift Technologies
$1.41 /

-0.025 (-1.75%)

04/28/22 William Blair
William Blair downgrades Vroom on 'very rough start' to Q2
03/30/22 Piper Sandler
Shift Technologies price target lowered to $10 from $17 at Piper Sandler
03/16/22 Northland
Shift Technologies price target lowered to $6 from $12 at Northland
03/16/22 DA Davidson
Shift Technologies price target lowered to $3 from $7 at DA Davidson
SV Spring Valley Acquisition Corp.
$10.10 /

+0.2 (+2.02%)

06/15/21 Lake Street
Spring Valley Acquisition Corp. initiated with a Buy at Lake Street
NFE New Fortress Energy
$39.98 /

-0.06 (-0.15%)

04/07/22 Credit Suisse
New Fortress Energy price target raised to $49 from $40 at Credit Suisse
04/04/22 Stifel
New Fortress Energy price target raised to $68 from $45 at Stifel
01/20/22 Barclays
New Fortress Energy price target lowered to $29 from $32 at Barclays
11/04/21 JMP Securities
New Fortress Energy price target lowered to $56 from $69 at JMP Securities
MMAT Meta Materials
$1.19 /

-0.045 (-3.64%)

STRY Starry
$8.29 /

+0.85 (+11.42%)

04/25/22 Goldman Sachs
Starry initiated with a Buy at Goldman Sachs
FRO Frontline
$8.50 /

+0.205 (+2.47%)

04/27/22 Jefferies
Frontline reinstated with a Hold at Jefferies
04/27/22 Jefferies
Euronav NV downgraded to Hold at Jefferies after merger announcement
04/08/22 H.C. Wainwright
Frontline price target raised to $9 from $8 at H.C. Wainwright
06/30/21 Danske Bank
Frontline upgraded to Buy from Hold at Danske Bank
CELU Celularity
$12.11 /

+0.15 (+1.25%)

04/06/22 Truist
Celularity downgraded to Hold from Buy at Truist
04/01/22 Oppenheimer
Celularity price target raised to $10 from $9 at Oppenheimer
01/27/22 Oppenheimer
Celularity initiated with an Outperform at Oppenheimer
11/24/21 Morgan Stanley
Celularity initiated with an Equal Weight at Morgan Stanley
CLVR Clever Leaves
$1.47 /

+0.03 (+2.09%)

03/28/22 Cowen
Clever Leaves price target lowered to $4 from $6 at Cowen
02/10/22 Canaccord
Clever Leaves price target lowered to $7 from $10 at Canaccord
12/23/21 Canaccord
Clever Leaves price target lowered to $10 from $12 at Canaccord
11/12/21 Cowen
Clever Leaves price target lowered to $6 from $11 at Cowen
ESSC East Stone Acquisition
$10.56 /

-0.09 (-0.85%)

SFT Shift Technologies
$1.41 /

-0.025 (-1.75%)

NFE New Fortress Energy
$39.98 /

-0.06 (-0.15%)

FRO Frontline
$8.50 /

+0.205 (+2.47%)

CLVR Clever Leaves
$1.47 /

+0.03 (+2.09%)

CELU Celularity
$12.11 /

+0.15 (+1.25%)

  • 20
    Oct
STRY Starry
$8.29 /

+0.85 (+11.42%)

MMAT Meta Materials
$1.19 /

-0.045 (-3.64%)

SFT Shift Technologies
$1.41 /

-0.025 (-1.75%)

MMAT Meta Materials
$1.19 /

-0.045 (-3.64%)

FRO Frontline
$8.50 /

+0.205 (+2.47%)

CLVR Clever Leaves
$1.47 /

+0.03 (+2.09%)

CELU Celularity
$12.11 /

+0.15 (+1.25%)

SV Spring Valley Acquisition Corp.
$10.10 /

+0.2 (+2.02%)

STRY Starry
$8.29 /

+0.85 (+11.42%)

SFT Shift Technologies
$1.41 /

-0.025 (-1.75%)

MMAT Meta Materials
$1.19 /

-0.045 (-3.64%)

FRO Frontline
$8.50 /

+0.205 (+2.47%)

ESSC East Stone Acquisition
$10.56 /

-0.09 (-0.85%)

CLVR Clever Leaves
$1.47 /

+0.03 (+2.09%)

CELU Celularity
$12.11 /

+0.15 (+1.25%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.